

David A Cameron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3696909/publications.pdf>

Version: 2024-02-01

227
papers

35,035
citations

9264

74
h-index

3407

183
g-index

231
all docs

231
docs citations

231
times ranked

26442
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 1659-1672.	27.0	4,601
2	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet, The</i> , 2014, 384, 164-172.	13.7	3,224
3	Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2006, 355, 2733-2743.	27.0	3,119
4	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1738-1748.	27.0	1,390
5	2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. <i>Lancet, The</i> , 2007, 369, 29-36.	13.7	1,361
6	Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1262-1271.	6.3	1,048
7	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 387, 9-20.	27.0	854
8	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	27.0	789
9	11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. <i>Lancet, The</i> , 2017, 389, 1195-1205.	13.7	770
10	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 533-543.	2.5	732
11	Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. <i>Lancet Oncology, The</i> , 2015, 16, 266-273.	10.7	709
12	Triple-negative breast cancer: disease entity or title of convenience?. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 683-692.	27.6	708
13	Identification of molecular apocrine breast tumours by microarray analysis. <i>Oncogene</i> , 2005, 24, 4660-4671.	5.9	694
14	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. <i>Lancet Oncology, The</i> , 2011, 12, 236-244.	10.7	575
15	A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. <i>Nature Medicine</i> , 2009, 15, 68-74.	30.7	566
16	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. <i>Lancet, The</i> , 2013, 382, 1021-1028.	13.7	447
17	Breast-Cancer Adjuvant Therapy with Zoledronic Acid. <i>New England Journal of Medicine</i> , 2011, 365, 1396-1405.	27.0	429
18	Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 1508-1516.	1.5	401

#	ARTICLE	IF	CITATIONS
19	Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 933-942.	10.7	370
20	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	1.6	331
21	The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. <i>Human Reproduction</i> , 2006, 21, 2583-2592.	0.9	323
22	1st International consensus guidelines for advanced breast cancer (ABC 1). <i>Breast</i> , 2012, 21, 242-252.	2.2	291
23	Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 4883-4890.	1.6	287
24	Lapatinib Plus Capecitabine in Women with HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial. <i>Oncologist</i> , 2010, 15, 924-934.	3.7	277
25	Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG) Tj ETQq1 1 0.784314 rgBT /Ov	10.7	247
26	Breast cancer in pregnancy: Recommendations of an international consensus meeting. <i>European Journal of Cancer</i> , 2010, 46, 3158-3168.	2.8	238
27	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. <i>Lancet</i> , The, 2019, 393, 2599-2612.	13.7	225
28	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 942-950.	27.0	220
29	Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer. <i>Oncologist</i> , 2011, 16, 1092-1100.	3.7	215
30	Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1131-1137.	1.6	214
31	Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. <i>Annals of Oncology</i> , 2003, 14, 1391-1398.	1.2	209
32	Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). <i>Journal of Clinical Oncology</i> , 2014, 32, 2159-2165.	1.6	207
33	Pretreatment Serum Anti-Müllerian Hormone Predicts Long-Term Ovarian Function and Bone Mass after Chemotherapy for Early Breast Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1336-1343.	3.6	200
34	Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. <i>Lancet Oncology</i> , The, 2020, 21, 1296-1308.	10.7	196
35	Multi-omic machine learning predictor of breast cancer therapy response. <i>Nature</i> , 2022, 601, 623-629.	27.8	187
36	Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen. <i>Journal of Clinical Oncology</i> , 2008, 26, 1948-1955.	1.6	176

#	ARTICLE	IF	CITATIONS
37	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). <i>Lancet Oncology</i> , The, 2013, 14, 244-248.	10.7	172
38	Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. <i>Annals of Oncology</i> , 2008, 19, 1090-1096.	1.2	168
39	Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. <i>Lancet</i> , The, 2009, 373, 1681-1692.	13.7	168
40	Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 2988-2995.	1.6	166
41	Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw050.	6.3	166
42	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2011, 12, 1134-1142.	10.7	165
43	HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 7861-7870.	7.0	159
44	Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study. <i>British Journal of Cancer</i> , 2001, 84, 1146-1149.	6.4	156
45	Letrozole Suppresses Plasma Estradiol and Estrone Sulphate More Completely Than Anastrozole in Postmenopausal Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1671-1676.	1.6	156
46	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	10.7	148
47	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology</i> , The, 2021, 22, 1139-1150.	10.7	147
48	Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. <i>British Journal of Cancer</i> , 2005, 92, 1869-1876.	6.4	144
49	Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. <i>Clinical Cancer Research</i> , 2010, 16, 2688-2695.	7.0	137
50	What Are the Current Standards of Care and Recent Developments in the Management of Breast Cancer?. <i>Oncologist</i> , 2006, 11, 1-3.	3.7	129
51	ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. <i>Contemporary Clinical Trials</i> , 2016, 51, 56-64.	1.8	129
52	Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. <i>Journal of Clinical Oncology</i> , 2007, 25, 2006-2011.	1.6	126
53	Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). <i>Lancet Oncology</i> , The, 2010, 11, 266-274.	10.7	122
54	TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2011, 12, 527-539.	10.7	116

#	ARTICLE	IF	CITATIONS
55	Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTEMIS): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 656-666.	10.7	114
56	The requirements of a specialist breast centre. <i>Breast</i> , 2020, 51, 65-84.	2.2	111
57	Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. <i>British Journal of Cancer</i> , 2003, 89, 1837-1842.	6.4	108
58	Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 3404-3411.	2.8	108
59	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. <i>European Journal of Cancer</i> , 2017, 70, 146-155.	2.8	108
60	High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. <i>Gut</i> , 2017, 66, 89-96.	12.1	107
61	Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. <i>Breast Cancer Research</i> , 2010, 12, R47.	5.0	104
62	Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 429-438.	2.5	97
63	Reduced MLH1 Expression in Breast Tumors After Primary Chemotherapy Predicts Disease-Free Survival. <i>Journal of Clinical Oncology</i> , 2000, 18, 87-87.	1.6	96
64	Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 5027-5035.	1.6	90
65	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 295-300.	2.5	89
66	Increase in response rate by prolonged treatment with neoadjuvant letrozole. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 145-151.	2.5	89
67	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 87-96.	6.3	89
68	Continuous 5-fluorouracil in the treatment of breast cancer. <i>British Journal of Cancer</i> , 1994, 70, 120-124.	6.4	88
69	Letrozole as Primary Medical Therapy for Locally Advanced and Large Operable Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2001, 66, 191-199.	2.5	87
70	Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 453-460.	2.3	86
71	Aromatase inhibitors and arthralgia. <i>Journal of Clinical Oncology</i> , 2001, 19, 2767.	1.6	83
72	The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, a Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients. <i>Annals of Oncology</i> , 2004, 15, 211-217.	1.2	79

#	ARTICLE	IF	CITATIONS
73	Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. <i>Annals of Oncology</i> , 2013, 24, 355-361.	1.2	78
74	Maximizing clinical benefit with trastuzumab. <i>Seminars in Oncology</i> , 2004, 31, 35-44.	2.2	75
75	Drug Insight: intracellular inhibitors of HER2â€”clinical development of lapatinib in breast cancer. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 512-520.	4.3	75
76	Economic Evaluation of Genomic Testâ€”Directed Chemotherapy for Early-Stage Lymph Nodeâ€”Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 56-66.	6.3	75
77	Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2009, 15, 1487-1495.	7.0	71
78	Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy. <i>British Journal of Cancer</i> , 1997, 76, 1099-1105.	6.4	70
79	Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 106, 461-468.	1.4	67
80	Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) â€”Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4423-4430.	1.6	66
81	Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1076-1083.	6.3	64
82	In situ detection of HER2:HER2 and HER2:HER3 proteinâ€”protein interactions demonstrates prognostic significance in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 463-470.	2.5	63
83	Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 805-814.	2.5	62
84	Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer. <i>Seminars in Oncology</i> , 2004, 31, 45-50.	2.2	61
85	Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 929-945.	10.7	58
86	Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial ABO1. <i>Journal of Clinical Oncology</i> , 2005, 23, 8322-8330.	1.6	57
87	Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. <i>Annals of Oncology</i> , 2008, 19, 877-882.	1.2	57
88	The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 1997, 44, 123-133.	2.5	56
89	Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 93-100.	4.1	56
90	Predicting Anthracycline Benefit: <i>TOP2A</i> and CEP17â€”Not Only but Also. <i>Journal of Clinical Oncology</i> , 2015, 33, 1680-1687.	1.6	55

#	ARTICLE	IF	CITATIONS
91	Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 79, 103-107.	2.5	54
92	Insulin-like Growth Factor Binding Proteins IGFBP3, IGFBP4, and IGFBP5 Predict Endocrine Responsiveness in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1438-1444.	7.0	54
93	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-202.	2.8	53
94	Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 577-589.	2.5	52
95	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. <i>Journal of Clinical Oncology</i> , 2021, 39, 2720-2731.	1.6	52
96	Current perspective “ Trastuzumab. <i>European Journal of Cancer</i> , 2009, 45, 12-18.	2.8	51
97	Adjuvant chemotherapy in older women (ACTION) study “ what did we learn from the pilot phase?. <i>British Journal of Cancer</i> , 2011, 105, 1260-1266.	6.4	51
98	Lessons from the use of aromatase inhibitors in the neoadjuvant setting.. <i>Endocrine-Related Cancer</i> , 1999, 6, 227-230.	3.1	49
99	Endocrine therapy resistance can be associated with high estrogen receptor $\hat{\pm}$ (ER $\hat{\pm}$) expression and reduced ER $\hat{\pm}$ phosphorylation in breast cancer models. <i>Endocrine-Related Cancer</i> , 2006, 13, 1121-1133.	3.1	49
100	Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer. <i>Pharmacoeconomics</i> , 2011, 29, 415-432.	3.3	48
101	Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 854-862.	8.1	47
102	Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. <i>Breast Cancer Research and Treatment</i> , 1997, 45, 99-107.	2.5	45
103	Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. <i>Lancet Oncology</i> , The, 2017, 18, 1543-1552.	10.7	45
104	Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer. <i>British Journal of Cancer</i> , 2006, 95, 1626-1631.	6.4	44
105	Osteonecrosis of the Jaw and Oral Health“Related Quality of Life After Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04). <i>Journal of Clinical Oncology</i> , 2013, 31, 2685-2691.	1.6	41
106	A Comparative Study of Exemestane Versus Anastrozole in Patients with Postmenopausal Breast Cancer with Visceral Metastases. <i>Clinical Breast Cancer</i> , 2009, 9, 39-44.	2.4	40
107	Anti-MÅ¼llerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. <i>Human Reproduction Update</i> , 2022, 28, 417-434.	10.8	40
108	Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. <i>Carcinogenesis</i> , 2006, 27, 729-739.	2.8	39

#	ARTICLE	IF	CITATIONS
109	Strengthening clinical cancer research in the United Kingdom. <i>British Journal of Cancer</i> , 2011, 104, 1529-1534.	6.4	39
110	Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1954-1960.	1.6	39
111	Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. <i>Breast Cancer Research</i> , 2010, 12, R39.	5.0	37
112	Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady-State Serum Concentrations and Is Well Tolerated. <i>Journal of Clinical Oncology</i> , 2010, 28, 960-966.	1.6	37
113	Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. <i>European Journal of Cancer</i> , 2012, 48, 3439-3447.	2.8	37
114	A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer. <i>European Journal of Cancer</i> , 2014, 50, 2367-2374.	2.8	37
115	Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node-Positive Breast Cancer: A Cost-Effectiveness and Cost-Utility Analysis. <i>Journal of Clinical Oncology</i> , 2008, 26, 925-933.	1.6	36
116	Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 32-40.	3.0	36
117	Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments. <i>European Journal of Cancer</i> , 2021, 144, 310-316.	2.8	34
118	Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. <i>British Journal of Cancer</i> , 2007, 97, 479-485.	6.4	33
119	Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. <i>British Journal of Cancer</i> , 2008, 99, 711-715.	6.4	33
120	Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study. <i>European Journal of Cancer</i> , 2017, 79, 226-234.	2.8	33
121	Predictive signatures for chemotherapy sensitivity in breast cancer: Are they ready for use in the clinic?. <i>European Journal of Cancer</i> , 2009, 45, 1733-1743.	2.8	32
122	Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 871-879.	6.3	32
123	On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 73.	5.0	32
124	Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. <i>Histopathology</i> , 2007, 51, 219-226.	2.9	31
125	Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. <i>Value in Health</i> , 2017, 20, 1311-1318.	0.3	31
126	Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles. <i>Artificial Intelligence in Medicine</i> , 2019, 97, 27-37.	6.5	30

#	ARTICLE	IF	CITATIONS
127	Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. <i>British Journal of Cancer</i> , 2020, 123, 852-859.	6.4	30
128	Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. <i>Journal of Pathology</i> , 2012, 227, 481-489.	4.5	29
129	Assessment of the Effect of Chemotherapy on Ovarian Function in Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1630-1631.	1.6	28
130	Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. <i>Oncogene</i> , 2010, 29, 5231-5240.	5.9	28
131	Tamoxifen treatment failure in cancer and the nonlinear dynamics of TGF β ² . <i>Journal of Theoretical Biology</i> , 2004, 229, 101-111.	1.7	27
132	Histological grading of invasive breast carcinoma – a simplification of existing methods in a large conservation series with long-term follow-up. <i>Histopathology</i> , 2009, 55, 724-731.	2.9	27
133	Chromosome instability and benefit from adjuvant anthracyclines in breast cancer. <i>British Journal of Cancer</i> , 2012, 107, 71-74.	6.4	27
134	Breast cancer patients'™ experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). <i>Breast</i> , 2004, 13, 363-368.	2.2	25
135	Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 449-458.	1.6	25
136	Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. <i>British Journal of Cancer</i> , 1996, 74, 2008-2012.	6.4	24
137	Ibandronate: Its Role in Metastatic Breast Cancer. <i>Oncologist</i> , 2006, 11, 27-33.	3.7	24
138	Trastuzumab-associated cardiac events in the Persephone trial. <i>British Journal of Cancer</i> , 2016, 115, 1462-1470.	6.4	23
139	Safety of Oral Ibandronate in the Treatment of Bone Metastases from Breast Cancer. <i>Clinical Drug Investigation</i> , 2006, 26, 43-48.	2.2	21
140	Progressive Loss of Estrogen Receptor β Cofactor Recruitment in Endocrine Resistance. <i>Molecular Endocrinology</i> , 2007, 21, 2615-2626.	3.7	21
141	Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. <i>European Journal of Health Economics</i> , 2012, 13, 589-603.	2.8	21
142	Advancing cancer drug discovery towards more agile development of targeted combination therapies. <i>Future Medicinal Chemistry</i> , 2012, 4, 87-105.	2.3	19
143	Species differences in tumour responses to cancer chemotherapy. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140233.	4.0	19
144	A prognostic index for operable, node-negative breast cancer. <i>British Journal of Cancer</i> , 2004, 90, 1933-1941.	6.4	18

#	ARTICLE	IF	CITATIONS
145	An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK. <i>Pharmacoeconomics</i> , 2009, 27, 847-859.	3.3	18
146	Impact of Screening and Risk Factors for Local Recurrence and Survival After Conservative Surgery and Radiotherapy for Early Breast Cancer: Results From a Large Series With Long-Term Follow-Up. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 829-838.	0.8	18
147	Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 755-769.	10.7	18
148	Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer. <i>British Journal of Cancer</i> , 2008, 99, 1984-1990.	6.4	17
149	The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. <i>European Journal of Cancer</i> , 2008, 44, 353-365.	2.8	17
150	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 936-944.	1.6	17
151	Infusional 5-fluorouracil in breast cancer. <i>Cancer Treatment Reviews</i> , 1994, 20, 357-364.	7.7	16
152	The p160 ER co-regulators predict outcome in ER negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 463-472.	2.5	16
153	Overall survival in MERiDIAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , 2018, 90, 153-155.	2.8	15
154	The challenges of making informed decisions about treatment and trial participation following a cancer diagnosis: a qualitative study involving adolescents and young adults with cancer and their caregivers. <i>BMC Health Services Research</i> , 2020, 20, 25.	2.2	15
155	Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. <i>Breast</i> , 2003, 12, S22-S29.	2.2	14
156	Health economics in drug development: Efficient research to inform healthcare funding decisions. <i>European Journal of Cancer</i> , 2010, 46, 2674-2680.	2.8	14
157	Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. <i>British Journal of Cancer</i> , 2012, 107, 1257-1267.	6.4	14
158	FKBPL: a marker of good prognosis in breast cancer. <i>Oncotarget</i> , 2015, 6, 12209-12223.	1.8	13
159	Locally advanced breast cancer: the outcome of primary polychemotherapy based on infusional 5 fluorouracil. <i>Breast</i> , 1999, 8, 110-115.	2.2	12
160	Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response. <i>British Journal of Cancer</i> , 2000, 83, 98-103.	6.4	12
161	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. <i>European Journal of Cancer</i> , 2022, 166, 219-228.	2.8	12
162	Patient management issues in metastatic bone disease. <i>Seminars in Oncology</i> , 2004, 31, 79-82.	2.2	11

#	ARTICLE	IF	CITATIONS
163	Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm. <i>Cancer Imaging</i> , 2010, 10, 144-152.	2.8	11
164	Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. <i>British Journal of Cancer</i> , 2019, 120, 913-921.	6.4	11
165	Six versus 12 monthsâ€™™ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-190.	2.8	11
166	Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 456-8.	0.3	11
167	Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptorâ€™™Positive, Human Epidermal Growth Factor Receptor 2â€™™Negative Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3699-3708.	1.6	11
168	Mathematical modelling of tumour response in primary breast cancer. <i>British Journal of Cancer</i> , 1996, 73, 1409-1416.	6.4	10
169	Cell killing and resistance in pre-operative breast cancer chemotherapy. <i>BMC Cancer</i> , 2008, 8, 201.	2.6	10
170	Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 787-794.	2.5	10
171	Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 773-781.	2.5	9
172	High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancerâ€“phase I/II study. <i>British Journal of Cancer</i> , 1996, 74, 2013-2017.	6.4	7
173	The Royal College of Physicians Simms Lecture, 6 December 2011: Clinical research networks and the benefits of intensive healthcare systems. <i>Clinical Medicine</i> , 2012, 12, 446-452.	1.9	7
174	Pertuzumab for the treatment of metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 907-918.	2.4	7
175	Breast cancer chemoprevention: little progress in practice?. <i>Lancet, The</i> , 2014, 383, 1018-1020.	13.7	7
176	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 127-132.	2.5	7
177	Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. <i>Clinical Cancer Research</i> , 2022, 28, 1323-1334.	7.0	7
178	Intraoperative radiotherapy for early breast cancer. <i>Lancet, The</i> , 2010, 376, 1142.	13.7	6
179	Adjuvant trastuzumab duration trials in HER2 positive breast cancer â€™™ what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. <i>BMC Cancer</i> , 2018, 18, 391.	2.6	6
180	Block sequential adriamycin CMF â€™™ optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?. <i>British Journal of Cancer</i> , 2002, 87, 1365-1369.	6.4	5

#	ARTICLE	IF	CITATIONS
181	Lapatinib for inflammatory breast cancer. <i>Lancet Oncology</i> , The, 2009, 10, 538-539.	10.7	5
182	Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer – An AZURE (BIG 01/04) sub-study. <i>Journal of Bone Oncology</i> , 2017, 9, 48-54.	2.4	5
183	Breast cancer gene expression datasets do not reflect the disease at the population level. <i>Npj Breast Cancer</i> , 2020, 6, 39.	5.2	5
184	Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review. <i>Breast</i> , 2022, 63, 85-100.	2.2	5
185	Bevacizumab: the first anti-angiogenic agent approved for the treatment of metastatic breast cancer. <i>European Journal of Cancer</i> , Supplement, 2008, 6, 1-6.	2.2	4
186	The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions. <i>European Journal of Cancer</i> , Supplement, 2012, 10, 27-33.	2.2	4
187	Removing the primary tumour in metastatic breast cancer. <i>Lancet Oncology</i> , The, 2015, 16, 1284-1285.	10.7	4
188	England's 30-day chemotherapy mortality: a measure of quality of care?. <i>Lancet Oncology</i> , The, 2016, 17, 1172-1173.	10.7	4
189	Postcode prescribing is alive and well in Scotland. <i>BMJ: British Medical Journal</i> , 2002, 325, 101a-101.	2.3	4
190	Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial. <i>Cancer Research</i> , 2022, 82, PD10-05-PD10-05.	0.9	4
191	Code of practice needed for samples donated by trial participants. <i>Lancet Oncology</i> , The, 2022, 23, e89-e90.	10.7	4
192	A pilot study of infusional CMF (CMF-inf): Active and well tolerated in breast cancer. <i>Annals of Oncology</i> , 1996, 7, 409-411.	1.2	3
193	Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case against. <i>Breast Cancer Research</i> , 2008, 10, S8.	5.0	3
194	Expression of activated type I receptor tyrosine kinases in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 701-708.	2.5	3
195	Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?. <i>Breast Cancer Research</i> , 2013, 15, R31.	5.0	3
196	Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 507-515.	2.5	3
197	Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer. <i>European Journal of Cancer</i> , 2017, 72, 95-102.	2.8	3
198	Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1356-1364.	6.4	3

#	ARTICLE	IF	CITATIONS
199	Modelling the Effects of Paclitaxel and Cisplatin on Breast and Ovarian Cancer. Journal of Theoretical Medicine, 2000, 3, 11-23.	0.5	2
200	Foundation clinical trials. Breast Cancer Research, 2009, 11, S23.	5.0	2
201	Developing an international network for breast cancer research: the BIG experience. Clinical Investigation, 2011, 1, 623-628.	0.0	2
202	Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. Breast Cancer Research and Treatment, 2016, 155, 303-311.	2.5	2
203	Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs).. Journal of Clinical Oncology, 2022, 40, 1083-1083.	1.6	2
204	Brachial plexopathy affecting the development of Beau's lines unilaterally. Lancet Oncology, The, 2001, 2, 342.	10.7	1
205	Breast cancer vaccines: current research and future prospects. Expert Review of Vaccines, 2002, 1, 29-34.	4.4	1
206	Role of bisphosphonate therapy in breast cancer and other advanced malignancies. Breast, 2003, 12, S20-S21.	2.2	1
207	Chemotherapy, Trastuzumab, and Pathological Complete Response: When Shall We Three Meet Again?. Journal of Clinical Oncology, 2011, 29, 3344-3345.	1.6	1
208	Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial. Breast Cancer Research and Treatment, 2018, 169, 497-505.	2.5	1
209	Strategies for improving access to clinical trials by teenagers and young adults with cancer: A qualitative study of health professionals' views. European Journal of Cancer Care, 2021, 30, e13408.	1.5	1
210	Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8-11, 2020. Breast Care, 2021, 16, 89-93.	1.4	1
211	Treatment of Screen-Detected Breast Cancer: Can We Avoid or Minimize Overtreatment?. , 2016, , 375-401.		1
212	Breast Cancer Therapy Annual "today's drug treatment of cancer?. Breast Cancer Research, 2003, 6, 1.	5.0	0
213	Should all adjuvant breast cancer patients receive a bisphosphonate?. Breast Cancer Research, 2003, 5, 296-9.	5.0	0
214	Paclitaxel in Early Breast Cancer. Drugs, 2004, 64, 1848-1849.	10.9	0
215	Time for a change in breast cancer therapy?. British Journal of Hospital Medicine, 2004, 65, 724-729.	0.2	0
216	Promises borne out in clinical studies. European Journal of Cancer, Supplement, 2008, 6, 15-24.	2.2	0

#	ARTICLE	IF	CITATIONS
217	Lapatinib in the management of breast cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 553-568.	0.2	0
218	Authors' Reply. <i>Journal of Pathology</i> , 2013, 229, e2-3.	4.5	0
219	Concerns about cardiotoxicity in the HERA trial – Authors' reply. <i>Lancet, The</i> , 2017, 390, 2767-2768.	13.7	0
220	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. <i>Anticancer Research</i> , 2019, 39, 797-802.	1.1	0
221	Protective strategies to prevent trastuzumab-induced cardiotoxicity – Authors' reply. <i>Lancet, The</i> , 2020, 395, 492-493.	13.7	0
222	Abstract OT-14-01: Adaption of the EORTC quality of life breast cancer module for male breast cancer - phase I. , 2021, , .		0
223	Adjuvant Systemic Treatment for Breast Cancer: An Overview. , 2016, , 311-321.		0
224	Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ER β , and cell-cycle signaling in a breast cancer model. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2022, 3, 97-116.	0.8	0
225	Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBC randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC). <i>Cancer Research</i> , 2022, 82, PD9-08-PD9-08.	0.9	0
226	Scottish COVID CAncer iMmunity Prevalence (SCCAMP): A longitudinal study of patients with cancer receiving active anti-cancer treatment during the COVID-19 pandemic.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18733-e18733.	1.6	0
227	Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12084-12084.	1.6	0